Scientists at the Fralin Biomedical Research Institute identified a subtype of immune cells that helps advanced prostate cancer evade the body’s defenses, suggesting a new approach for treatment.
Shenglin Mei, the newest principal investigator of the Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C., applies computational biology, genetics, and immunology to study cancer’s spread away from the primary tumor.